ADOCIA Announces Full Year 2024 Financial Results and Provides a Corporate and Financial Update
LYON, France, April 17, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the "Company"), announces today its annual financial results as of December 31, 2024. The consolidated statements contained herein were approved by Adocia’s board of directors on April 16, 2025. Audit procedures have been completed, and the audi